Healthcare Industry News: Microvolt T-Wave Alternans
News Release - November 6, 2006
Results from St. Jude Medical's Study of Microvolt T-Wave Alternans to be Presented at the 2006 American Heart Association Scientific Sessions
ST. PAUL, Minn., and BEDFORD, Mass.--(HSMN NewsFeed)--St. Jude Medical, Inc. (NYSE:STJ ) and Cambridge Heart, Inc. (OTCBB:CAMH ) today announced that the findings of the Alternans Before Cardioverter Defibrillator (ABCD) clinical study will be presented at the American Heart Association (AHA) 2006 Annual Scientific Sessions in Chicago, Ill.The ABCD clinical study results will be presented at the AHA's Late Breaking Clinical Trials sessions on Wednesday, Nov. 15.
The study compared the predictive value of Cambridge Heart's noninvasive Microvolt T-Wave Alternans Test(TM) with standard, invasive electrophysiology tests in identifying patients at high risk for sudden cardiac death, a condition that kills more than 400,000 Americans each year. The trial was conducted at 42 clinical centers around the world.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac, neurological and chronic pain patients worldwide through excellence in medical device technology and services. The Company has five major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation. Headquartered in St. Paul, Minn., St. Jude Medical employs approximately 11,000 people worldwide. For more information, please visit www.sjm.com.
About Cambridge Heart
Cambridge Heart (www.cambridgeheart.com) is engaged in the development and commercialization of products for the non-invasive diagnosis of cardiac disease, particularly the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary Microvolt T-Wave Alternans measurement technologies, coupled with its patented Spectral Analytic Method and ultra-sensitive disposable electrodes. Only Spectral Analytic Method MTWA tests are reimbursed by Medicare under its National Coverage Policy that covers patients with a wide variety of cardiac symptoms. Other major insurers in the USA also have coverage policies for the test. The T-Wave Alternans test is included in the Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death jointly developed by the American College of Cardiology (ACC), The American Heart Association (AHA) and the European Society of Cardiology (ESC).
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, regulatory approvals, anticipated future product launches, revenues, margins, earnings, and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's Annual Report on Form 10-K filed on March 16, 2006 (see Item 1A on pages 15-21) and in the Company's Quarterly Report on Form 10-Q filed on August 7, 2006 (see page 31 and Item 1A on page 32). The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
Source: St. Jude Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
